These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 9875395)

  • 21. In vitro anti-HIV-1 synergy between non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz.
    Kollmann C; Tremblay C; Giguel F; Chou TC; Hirsch MS
    Antivir Ther; 2001 Jun; 6(2):143-4. PubMed ID: 11491419
    [No Abstract]   [Full Text] [Related]  

  • 22. Rational design and synthesis of novel thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Murugesan V; Makwana N; Suryawanshi R; Saxena R; Tripathi R; Paranjape R; Kulkarni S; Katti SB
    Bioorg Med Chem; 2014 Jun; 22(12):3159-70. PubMed ID: 24794742
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor.
    McMahon JB; Buckheit RW; Gulakowski RJ; Currens MJ; Vistica DT; Shoemaker RH; Stinson SF; Russell JD; Bader JP; Narayanan VL; Schultz RJ; Brouwer WG; Felauer EE; Boyd MR
    J Pharmacol Exp Ther; 1996 Jan; 276(1):298-305. PubMed ID: 8558446
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sensitivity and resistance to (+)-calanolide A of wild-type and mutated forms of HIV-1 reverse transcriptase.
    Quan Y; Motakis D; Buckheit R; Xu ZQ; Flavin MT; Parniak MA; Wainberg MA
    Antivir Ther; 1999; 4(4):203-9. PubMed ID: 10723499
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of human immunodeficiency virus type 1 strains resistant to the non-nucleoside reverse transcriptase inhibitor RD4-2217.
    Fujiwara M; Kodama EN; Okamoto M; Tokuhisa K; Ide T; Hanasaki Y; Katsuura K; Takayama H; Aimi N; Mitsuya H; Shigeta S; Konno K; Yokota T; Baba M
    Antivir Chem Chemother; 1999 Nov; 10(6):315-20. PubMed ID: 10628806
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complete inhibition of viral breakthrough by combination of MKC-442 with AZT during a long-term culture of HIV-1 infected cells.
    Okamoto M; Makino M; Yamada K; Nakade K; Yuasa S; Baba M
    Antiviral Res; 1996 Jun; 31(1-2):69-77. PubMed ID: 8793010
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
    Cushman M; Casimiro-Garcia A; Hejchman E; Ruell JA; Huang M; Schaeffer CA; Williamson K; Rice WG; Buckheit RW
    J Med Chem; 1998 Jun; 41(12):2076-89. PubMed ID: 9622549
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and biological evaluation of certain alkenyldiarylmethanes as anti-HIV-1 agents which act as non-nucleoside reverse transcriptase inhibitors.
    Cushman M; Golebiewski WM; Graham L; Turpin JA; Rice WG; Fliakas-Boltz V; Buckheit RW
    J Med Chem; 1996 Aug; 39(16):3217-27. PubMed ID: 8759644
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The dolabellane diterpene Dolabelladienetriol is a typical noncompetitive inhibitor of HIV-1 reverse transcriptase enzyme.
    Cirne-Santos CC; Souza TM; Teixeira VL; Fontes CF; Rebello MA; Castello-Branco LR; Abreu CM; Tanuri A; Frugulhetti IC; Bou-Habib DC
    Antiviral Res; 2008 Jan; 77(1):64-71. PubMed ID: 17888523
    [TBL] [Abstract][Full Text] [Related]  

  • 30. APHS can act synergically with clinically available HIV-1 reverse transcriptase and protease inhibitors and is active against several drug-resistant HIV-1 strains in vitro.
    Pereira CF; Paridaen JT; van de Bovenkamp M; Middel J; Verhoef J; Nottet HS
    J Antimicrob Chemother; 2003 May; 51(5):1181-9. PubMed ID: 12668583
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Binding modes of two novel non-nucleoside reverse transcriptase inhibitors, YM-215389 and YM-228855, to HIV type-1 reverse transcriptase.
    Kodama E; Orita M; Masuda N; Yamomoto O; Fujii M; Ohgami T; Kageyama S; Ohta M; Hatta T; Inoue H; Suzuki H; Sudo K; Shimizu Y; Matsuoka M
    Antivir Chem Chemother; 2008; 19(3):133-41. PubMed ID: 19024630
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure-activity relationship studies of novel benzophenones leading to the discovery of a potent, next generation HIV nonnucleoside reverse transcriptase inhibitor.
    Romines KR; Freeman GA; Schaller LT; Cowan JR; Gonzales SS; Tidwell JH; Andrews CW; Stammers DK; Hazen RJ; Ferris RG; Short SA; Chan JH; Boone LR
    J Med Chem; 2006 Jan; 49(2):727-39. PubMed ID: 16420058
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.
    Andries K; Azijn H; Thielemans T; Ludovici D; Kukla M; Heeres J; Janssen P; De Corte B; Vingerhoets J; Pauwels R; de Béthune MP
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4680-6. PubMed ID: 15561844
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The anti-HIV activity of three 2-alkylsulfanyl-6-benzyl-3, 4-dihydropyrimidin-4 (3H)-one derivatives acting as non-nucleoside reverse transcriptase inhibitor in vitro.
    Long J; Zhang DH; Zhang GH; Rao ZK; Wang YH; Tam SC; He YP; Zheng YT
    Yao Xue Xue Bao; 2010 Feb; 45(2):228-34. PubMed ID: 21348416
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of the glycosyl moiety of myricetin derivatives in anti-HIV-1 activity in vitro.
    Ortega JT; Suárez AI; Serrano ML; Baptista J; Pujol FH; Rangel HR
    AIDS Res Ther; 2017 Oct; 14(1):57. PubMed ID: 29025433
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-human immunodeficiency virus type 1 (HIV-1) activity of 2'-fluoro-2',3'-dideoxyarabinosyladenine (F-ddA) used in combination with other mechanistically diverse inhibitors of HIV-1 replication.
    Buckheit RW; Russell JD; Pallansch LA; Driscoll JS
    Antivir Chem Chemother; 1999 May; 10(3):115-9. PubMed ID: 10431610
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiviral activity and mechanism of action of calanolide A against the human immunodeficiency virus type-1.
    Currens MJ; Gulakowski RJ; Mariner JM; Moran RA; Buckheit RW; Gustafson KR; McMahon JB; Boyd MR
    J Pharmacol Exp Ther; 1996 Nov; 279(2):645-51. PubMed ID: 8930167
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potent and specific inhibition of human immunodeficiency virus type 1 replication by 4-(2,6-dichlorophenyl)-1,2,5-thiadiazol-3-Y1 N,N-dialkylcarbamate derivatives.
    Ijichi K; Fujiwara M; Hanasaki Y; Watanabe H; Katsuura K; Takayama H; Shirakawa S; Sakai S; Shigeta S; Konno K
    Antimicrob Agents Chemother; 1995 Oct; 39(10):2337-40. PubMed ID: 8619592
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel 8-substituted dipyridodiazepinone inhibitors with a broad-spectrum of activity against HIV-1 strains resistant to non-nucleoside reverse transcriptase inhibitors.
    O'Meara JA; Yoakim C; Bonneau PR; Bös M; Cordingley MG; Déziel R; Doyon L; Duan J; Garneau M; Guse I; Landry S; Malenfant E; Naud J; Ogilvie WW; Thavonekham B; Simoneau B
    J Med Chem; 2005 Aug; 48(17):5580-8. PubMed ID: 16107158
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Substituted naphthalenones as a new structural class of HIV-1 reverse transcriptase inhibitors.
    Alam M; Bechtold CM; Patick AK; Skoog MT; Gant TG; Colonno RJ; Meyers AI; Li H; Trimble J; Lin PF
    Antiviral Res; 1993 Oct; 22(2-3):131-41. PubMed ID: 7506510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.